Cite
HARVARD Citation
Brown, J. et al. (n.d.). IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL. Hematological oncology. pp. 385-386. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Brown, J. et al. (n.d.). IDELALISIB PLUS ANTI‐CD20 USED SECOND LINE SHOWS IMPROVED PFS AND COMPARABLE SAFETY COMPARED TO LATER LINE THERAPY OF RELAPSED CLL. Hematological oncology. pp. 385-386. [Online].